References
Albin R, Young A, Penney J (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366–375
Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RSJ (1992) Striatal D2 receptor status in Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with11C-raclopride and PET. Ann Neurol 31:184–192
Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75:221–226
Colosimo C, Albanese A, Hughes AJ, de Bruin VMS, Lees AJ (1995) Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 52:294–298
Fahn S, Elton RL, Agid Y, Barbeau A, Calne DB, Duvoisin RC, Hoehn MM, Jankovic J, Klawans HL, Lang AE, Lataste X, Lieberman AN, Marsden CD, Markham CH, Mayeux R, Rinne UK, Stern GM, Teychenne P, Yahr MD (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M (eds) Recent developments in Parkinson's disease. MacMillan Healthcare Information, Florham Park, New Jersey, pp 153–163
Hughes AJ, Lees AJ, Stern GM (1990) Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 336:32–34
Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ (1992) The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 55:1009–1013
Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK801 binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206:297–300
Lees AJ (1987) The Steele-RichardsonOlszewski syndrome (progressive supranuclear palsy). In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, pp 272–287
Quinn N (1994) Multiple system atrophy. In: Fahn S, Marsden CD (eds) Movement disorders 3. ButterworthHeinemann, Oxford, pp 262–281
Riederer P, Kornhuber J, Gerlach M, Danielczyk W, Youdim MBH (1991) Glutamatergic-dopaminergic imbalance in Parkinson's disease and paranoid hallucinatory psychosis. In: Rinne UK, Nagatsu T, Horowski R (eds) How to proceed today in treatment. International workshop Berlin, Parkinson's disease. Medicom Europe, Bussum, pp 10–23 12. Riley D, Lang AE, Lewis A, Resch L, Ashby P, Homykiewicz O, Black J (1990) Cortical-basal ganglionic degeneration. Neurology 40:1203–1212
Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-parkinsonian drug amantadine inhibits theN-methyl-d-as-partic acid-evoked release of acetylcholine from rat neostriatum in a noncompetitive way. Eur J Pharmacol 213:439–443
Von Voigtlander P, Moore K (1970) Dopamine: release from the brain in vivo by amantadine. Science 174:408–410
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Colosimo, C., Merello, M. & Pontieri, F.E. Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. J Neurol 243, 422–425 (1996). https://doi.org/10.1007/BF00869004
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00869004